Trademark Overview
On Thursday, July 26, 2018, a trademark application was filed for ICONIMAC with the United States Patent and Trademark Office. The USPTO has given the ICONIMAC trademark a serial number of 88054356. The federal status of this trademark filing is ABANDONED - NO STATEMENT OF USE FILED as of Monday, September 21, 2020. This trademark is owned by Cellular Approaches, Inc.. The ICONIMAC trademark is filed in the Pharmaceutical Products and Computer & Software Services & Scientific Services categories with the following description:
Pharmaceuticals for the purpose of treating life-threatening diseases; pharmaceuticals for use in the fields of biotechnology and immune therapeutics; pharmaceutical products, namely, innate immunity cell-based therapeutics; pharmaceuticals for the treatment of infectious disease, autoimmunity, neurodegeneration, and aging; pharmaceuticals for addressing underlying innate immune dysfunction, including in connection with infectious diseases, autoimmune diseases, neurologic diseases, cancer, Parkinson's, Alzheimer's, and dementia; pharmaceuticals for addressing a wide variety of diseases, including pulmonary diseases, fibrosis, and protein aggregation diseases; pharmaceutical preparations, namely, cell-based therapeutics to augment innate immune responses; pharmaceutical preparations, namely, a drug delivery system for the continuous release of a wide variety of therapeutic agents; vaccines; vaccine preparations
Biotechnology research; immune therapeutics research; research and development in the biotechnology and immune therapeutics fields; development of new technology in the field of biotechnology to augment innate immune responses; development of new biotechnology, namely, using augmented innate immune responses to promote the treatment of infectious disease, autoimmunity, neurodegeneration, and aging; development of new biotechnology, namely, pharmaceuticals for addressing underlying innate immune dysfunction, including in connection with infectious diseases, autoimmune diseases, neurologic diseases, cancer, Parkinson's, Alzheimer's, and dementia; development of new biotechnology, namely, pharmaceuticals for addressing a wide variety of diseases, including pulmonary diseases, fibrosis, and protein aggregation diseases; conducting clinical trials in the field of biotechnology; clinical research in the field of immune therapeutics; clinical research in the field of vaccines; research and de...
